Starting Dose for Tirzepatide 11.25 mg/mL in Syringe Units
The starting dose of tirzepatide is 2.5 mg administered subcutaneously once weekly, which equals 0.22 mL when using the 11.25 mg/mL concentration. If your syringe is marked in units (where 1 mL = 100 units), this translates to 22 units 1.
Dosing Algorithm
Initial Dosing
- Start at 2.5 mg (0.22 mL or 22 units) once weekly for the first 4 weeks
- This low starting dose is essential to minimize gastrointestinal side effects, which are the most common adverse events with tirzepatide 1
Dose Escalation Schedule
After the initial 4-week period, escalate the dose monthly by 2.5 mg increments:
- Weeks 0-3: 2.5 mg (22 units)
- Weeks 4-7: 5 mg (44 units)
- Weeks 8-11: 7.5 mg (67 units)
- Weeks 12-15: 10 mg (89 units)
- Weeks 16-19: 12.5 mg (111 units)
- Week 20+: 15 mg maximum dose (133 units)
The FDA-approved therapeutic doses are 5 mg, 10 mg, and 15 mg weekly for both obesity and type 2 diabetes 1.
Critical Dosing Considerations
Slow titration is vital - the 2.5 mg starting dose with monthly 2.5 mg increments significantly reduces gastrointestinal side effects (nausea, vomiting, diarrhea) compared to more aggressive escalation 1, 2. Research demonstrates that lower starting doses and smaller increments result in better tolerability profiles 2.
Real-world dosing patterns show that 84.1% of patients initiate at ≤5 mg, and even at the sixth prescription refill, 56.5% remain on doses <10 mg 3. This suggests many patients achieve therapeutic benefit without reaching maximum doses.
If treatment is interrupted: Patients who discontinue or pause therapy must restart at the 2.5 mg dose and re-titrate upward to allow the body to re-acclimate to the medication 1.
Common Pitfalls to Avoid
- Do not start at higher doses - beginning above 2.5 mg substantially increases the risk of treatment-limiting gastrointestinal adverse events
- Do not escalate faster than monthly - the 4-week intervals between dose increases are evidence-based for tolerability 4, 5, 2
- Do not skip the starting dose after treatment gaps - even brief interruptions require restarting at 2.5 mg 1
The evidence consistently demonstrates that starting with the lowest dose of 2.5 mg (22 units when using 11.25 mg/mL concentration) and following the monthly escalation schedule optimizes both efficacy and tolerability while minimizing treatment discontinuation due to adverse events 1, 4, 2.